Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Tocilizumab in pJIA
NCT00144625Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2005
- Primary completion
- Jul 2005
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in polyarticular juvenile idiopathic arthritis, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Percentage of patients showing 30% improvement in the JIA core set, Incidence and severity of adverse events and adverse drug reactions and 1 more. Started Feb 2005; status: completed.
02
Drugs
tocilizumab
03
Conditions
polyarticular juvenile idiopathic arthritis
Beyond the preview
Go deeper on NCT00144625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144625.